We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01587521
First Posted: April 30, 2012
Last Update Posted: July 28, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sirijit Suttajit, Chiang Mai University
  Purpose

Patients with schizophrenia are more likely to have metabolic syndrome compared to general population. The criterion for metabolic syndrome in Asian people including: elevated waist circumference (male ≥ 90cm, female ≥ 80cm), elevated triglycerides ≥ 150mg/dL, reduced HDL cholesterol: male < 40mg/dL, female < 50mg/dL, elevated blood pressure: ≥ 130/85 mmHg, elevated fasting glucose: ≥ 100mg/dL. Several factors have been found to be associated with metabolic syndrome in schizophrenia, e.g. age, antipsychotic drugs, smoking, family history of metabolic disorder, stress, and quality of life.

However, little is known about the prevalence of and factors associated in Asian. This study aimed to:

  1. Identify the prevalence of metabolic syndrome in patients with schizophrenia.
  2. Identify the factors associated with metabolic syndrome in patients with schizophrenia.

Condition
Metabolic Syndrome Quality of Life Depression

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by Sirijit Suttajit, Chiang Mai University:

Enrollment: 80
Study Start Date: January 2012
Study Completion Date: June 2016
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Detailed Description:

Patients with schizophrenia are more likely to have metabolic syndrome compared to general population. The criterion for metabolic syndrome in Asian people including: elevated waist circumference (male ≥ 90cm, female ≥ 80cm), elevated triglycerides ≥ 150mg/dL, reduced HDL cholesterol: male < 40mg/dL, female < 50mg/dL, elevated blood pressure: ≥ 130/85 mmHg, elevated fasting glucose: ≥ 100mg/dL. Several factors have been found to be associated with metabolic syndrome in schizophrenia, e.g. age, antipsychotic drugs, smoking, family history of metabolic disorder, stress, and quality of life.

However, little is known about the prevalence of and factors associated in Asian. This study aimed to:

  1. Identify the prevalence of metabolic syndrome in patients with schizophrenia.
  2. Identify the factors associated with metabolic syndrome in patients with schizophrenia.

Method This study is a cross-sectional study conducting at the Faculty of Medicine, Chiang Mai University. Eighty participants will be recruited with the inclusion criteria of having diagnosed with schizophrenia according to DSM-IV-TR and aged 18 years or over. The exclusion criterion is having organic brain syndrome.

Measurements PANSS CDSS WHOQOL-BREF-THAI

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants diagnosed with schizophrenia
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia according to DSM-IV-TR
  • Aged 18 years-old or over

Exclusion Criteria:

  • Having organic brain syndromes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01587521


Locations
Thailand
Chiang Mai University
Chiang Mai, Thailand, 50200
Sponsors and Collaborators
Chiang Mai University
Investigators
Study Director: Sirijit Suttajit, MD. MSc. Chiang Mai University
  More Information

Responsible Party: Sirijit Suttajit, Assistant professor, Chiang Mai University
ClinicalTrials.gov Identifier: NCT01587521     History of Changes
Other Study ID Numbers: PSY-11-07-26A-12
First Submitted: April 26, 2012
First Posted: April 30, 2012
Last Update Posted: July 28, 2016
Last Verified: July 2016

Keywords provided by Sirijit Suttajit, Chiang Mai University:
Metabolic syndrome
Prevalence
Quality of life
Depression
Antipsychotics

Additional relevant MeSH terms:
Schizophrenia
Disease
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Glucose Metabolism Disorders
Metabolic Diseases
Syndrome
Depression
Metabolic Syndrome X
Pathologic Processes
Behavioral Symptoms
Insulin Resistance
Hyperinsulinism


To Top